Eli Lilly’s Stock Soars on Weight-Loss Drug Success and Market Leadership
Eli Lilly & Co.’s stock price has surged due to the success of its weight-loss drug Mounjaro/Zepbound and promising clinical trial results for additional treatments.
One minute to read